Human female reproductive aging features declining ovarian follicle reserve and oocyte quality, and rising levels of circulating follicle-stimulating hormone (FSH). We determined the effects of elevated FSH on oocyte-embryo development in mature mice exhibiting premature infertility caused by progressively rising transgenic human FSH (TgFSH) levels. Oocyte-embryo developmental competence and quality were examined using oocyte maturation and aneuploidy rates, biomarkers of oocyte quality, and reciprocal embryo transfers assessed for implantation and pregnancy. In vitro maturation suggested that TgFSH exposure only hindered oocyte developmental competence in old females, as significantly more oocytes from ≥12-month-old TgFSH females remained at germinal vesicle stage compared with age-matched control oocytes. Aneuploidy rates were equivalent in oocytes from aging TgFSH compared with wildtype females. Cumulus cell expression levels of candidate biomarker Inhba, Egfr, and Rgs2 transcripts were elevated in associated aneuploid vs euploid oocytes from both TgFSH and wildtype females. In vivo, embryos transferred from subfertile 6-month-old TgFSH females to wildtype recipients yielded normal implantation rates and more pups born compared with controls. Transfer of wildtype embryos rescued the fertility of 6-month-old TgFSH-recipient females, although pup birth weight was reduced in TgFSH vs wildtype recipients. Our current findings show that elevated FSH had minimal disruption of either embryo developmental capacity or uterine function when examined in isolation, and the subfertility of TgFSH female mice was not caused by altered oocyte aneuploidy or quality.
Introduction
Elevated basal circulating follicle-stimulating hormone (FSH) levels are an early feature of human female reproductive aging [1] [2] [3] [4] , coinciding with a significant decline in fertility [4, 5] , both of which occur before the onset of irregular menstrual cycles and complete follicle depletion (menopause). It was proposed that increased FSH is associated with the age-related acceleration in the decline of ovarian follicle reserve, and that higher FSH may not be solely a passive reflection of ovarian follicle pool size, but may also play an active role in follicle depletion [4] [5] [6] . It is possible that elevated FSH increases recruitment of follicles from a diminishing pool, including suboptimal follicles normally excluded from selection. Increased FSH actions may maintain the number of growing follicles at the expense of sacrificing oocyte quality [4, 7, 8] . In rats, premature reproductive aging due to partial ovariectomy is characterized by a compensatory rise in ovulation in the remaining ovary, elevated circulating FSH [9, 10] , and an earlier decline in embryo quality [11] . Unilateral ovariectomy in mice leads to premature reproductive failure and an early rise in embryonic aneuploidy [12] ; however, changes in circulating FSH were not determined. Exposure to high gonadotrophin dosage in a single mouse superovulation regimen induced abnormal oocytes [13, 14] and preimplantation embryos [15] , and reduced postimplantation development [16, 17] . In contrast, four repeated rounds of ovarian hyperstimulation by exogenous gonadotrophins decreased oocyte quality by in vitro parameters, but had no marked effect upon in vivo developmental competence of oocytes [18] . These models did not directly examine the isolated effects of elevated FSH nor did they distinguish between excessive FSH or LH actions. Although FSH dose dependently reduced oocyte quality in mouse cumulus-oocyte complexes (COCs) during in vitro maturation [19] , the in vivo consequences of long-term elevated FSH levels upon oocyte quality has yet to be established.
Our previous work showed that rising serum levels of transgenic FSH (TgFSH) induced premature infertility in female mice [20] , despite continued estrous cycling and ovulation, which is comparable with declining human female fertility that precedes menopause despite continuous cycling and ovulation [4] . Litter sizes from TgFSH females over 5 months of age rapidly declined, and in 6-month-old pregnant TgFSH females, approximately half of the implanted embryos underwent resorption [20] . The effect of high FSH levels on oocyte quality or uterine function was not selectively examined in this TgFSH model.
The current study has determined the effect of elevated FSH upon oocyte quality and embryo viability utilizing both in vivo and in vitro methods. In vitro analysis of oocyte quality investigated oocyte developmental capacity and aneuploidy in aging TgFSH females. Gene expression (Has2, Inhba, Egfr, Grem1, Tnfaip6, Ptgs2, Cyp19, Serpine2, Pgk1, Rgs2, Ctnnd2, and Cxcr4) in oocyte-matched cumulus cells (CCs) was examined to identify potential somatic biomarker transcripts of oocyte quality and any effects of high FSH. Reciprocal embryo transfers between TgFSH and wildtype (WT) females were used as a selective in vivo assessment into the effects of elevated FSH upon embryo development or uterine function. Our findings provide unique insight into in vitro and in vivo consequences of a monotrophic rise in circulating FSH and its impact upon oocyte quality and embryo developmental capacity.
Materials and methods

Genetic mouse model
All animal procedures were approved by the Animal Welfare Committee of the Sydney Local Health District and performed in accordance to the National Health and Medical Research Council code of practice for care and use of animals and the NSW Animal Research Act (1985) .
Mice
TgFSH mice expressing pituitary-independent bioactive heterodimeric human FSH using the rat insulin 2 gene promoter [Tg(Ins2-FSHB/Ins2-CGA)1Cmal] were created and maintained as previously described, denoted TgFSH mice in this paper [21] . The rat Ins2 promoter directs TgFSH expression independently of the HPG axis [21] . Our TgFSH model (previously referred to as TgFSH m for moderate FSH levels [22] ) expresses serum TgFSH levels up to ∼10 IU/L [20] . Age-and strain-matched TgFSH and non-Tg (WT) females were obtained by crossbreeding heterozygous TgFSH with WT animals. Resulting offspring were genotyped by PCR as previously described [20, 21] . Age-matched TgFSH and non-Tg female littermates used in experiments were housed under controlled conditions (12 h light-dark cycle) with ad lib access to food and water. Embryo transfer experiments described in this study used genotyped TgFSH and WT littermate age-matched donor females mated with fertile strain-matched WT males, and strain-matched-recipient WT or TgFSH females.
Genotyping
Genomic DNA samples isolated from toe or tail tip or ovary tissue were used for PCR genotyping to detect the alpha-and beta-subunit transgene using previously described primers and conditions [21] .
Oocyte collection and culture
Germinal vesicle (GV) stage oocytes were collected from naturally cycling TgFSH and WT females at 6, 12, 18, and 24 months of age and were used for in vitro maturation. Oocytes were cultured in M2 medium (Sigma-Aldrich, Sydney, Australia) containing 4% bovine serum albumin (BSA) (Sigma-Aldrich, Sydney, Australia) for bench handling or in Minimum Essential Medium-α (Sigma-Aldrich, Sydney, Australia), fetal calf serum (Sigma-Aldrich, Sydney, Australia), penicillin (Sigma-Aldrich, Sydney, Australia), and streptomycin (Sigma-Aldrich, Sydney, Australia) with 5% CO 2 in a humidified incubator at 37
• C for vitro maturation overnight [23, 24] .
Milrinone (10 μM, Sigma-Aldrich, Sydney, Australia) was used to maintain GV arrest after overnight maturation. ZM447439 (10 mM; Tocris Biosciences, Victoria, Australia) in dimethyl sulfoxide (SigmaAldrich, Sydney, Australia) was used at a dilution of 0.1% to stain centromere structures of the sister chromatids [25] .
Chromosomal kinetochore counting and ploidy quantitation
Oocytes were treated with monastrol (Sigma-Aldrich, Sydney, Australia) before fixation and permeabilization as described previously [25, 26] . Immunofluorescence was performed using antibodies to tubulin (1:400 dilution, Life Research, VIC, Australia) and CREST Table 1 .
Embryo transfer experiments
Embryos were transferred from 26-week-old TgFSH or WT donor females into 12-week-old WT or TgFSH-recipient females using standard transfer procedures [27] . Briefly, donor embryos were collected from the ampulla of the fallopian tube of females naturally mated with strain-matched fertile males, after 2 days of exposure to male cage bedding to synchronize estrous cycling. Pooled embryos from genotype-matched females were isolated in 0.5 mg/ml hyaluronidase (Sigma-Aldrich, Sydney, Australia) in warm M2 medium, then incubated at 37
• C for at least 1 h in M16 media (Sigma-Aldrich, Sydney, Australia) prior to surgical transfer. Pseudopregnant-recipient females, identified by the presence of a copulation plug after mating with vasectomized males, were anesthetized at 0.5 days postcoitum, and 8-10 pooled donor embryos were implanted into the left oviduct using glass transfer pipettes as described [28] . Recipients were examined for pregnancy and collected at 19 days postcoitum to determine the number of uterine implantation sites as described [20] , as well as the number of full-term pups, which were collected and weighed. The percentage of pregnant recipients, uterine implantations (total implantations and % implanted/embryos transferred), and full-term pups (total pups and % pups at term/implantation sites) were calculated. The higher than normal number of embryo implantation sites found in TgFSH females was avoided by unilateral embryo transfers using 8-10 embryos per mouse, similar to the number of implantation sites normally present in WT females. We separately investigated potential oocyte or uterine effects from elevated FSH exposure by using subfertile 26-week-old TgFSH females as embryo donors or recipients, respectively [20] .
Statistical analysis
Statistical analysis was performed using NCSS (NCSS Statistical Software) software. Statistical differences were tested by one-way or two-way ANOVA (to assess the effect of genotype (G), age (A) and ploidy status (Pl) and interactions of these effects) and suitable post hoc tests. Pregnancy rates were analyzed using a Fisher's exact test. Main effects of FSH, ploidy, and age status are reported using two-way ANOVA, interaction results omitted if not significant. P ≤ 0.05 was considered statistically significant (PRISM software version 3.03; GraphPad).
Results
Effect of age and TgFSH on oocyte developmental capacity
During in vitro maturation, a higher percentage (9%-15%) of oocytes from ≥12-month-old TgFSH females remained at the GV stage compared to oocytes from matched WT females (two-way ANOVA: age, P < 0.001; genotype, P < 0.001; interaction, P < 0.001) ( Figure 1A ). Oocytes from older TgFSH mice (≥12 months) had a significantly reduced progression to the MI stage compared with WT oocytes (two-way ANOVA: age, P < 0.001; genotype, P < 0.001; interaction, P < 0.001) ( Figure 1B ). Significantly less oocytes from ≥18-month-old TgFSH females reached the MII stage compared with age-matched WT oocytes (two-way ANOVA: age, P < 0.001; genotype, P < 0.001; interaction, P < 0.05) (Figure 1C) . The percentage of cell death increased with age and was equivalent between TgFSH and WT controls (two-way ANOVA: age, P < 0.0001; genotype, P = 0.62; interaction, P = 0.12) ( Figure  1D ).
Effect of age and TgFSH on oocyte aneuploidy
The proportion of aneuploid oocytes recovered from mice showed a significant age effect (two-way ANOVA: age, P < 0.001) (Figure 2 ). A significant difference was observed between 24-month-old WT and TgFSH mice due to the absence of euploid oocytes from TgFSH females (one-way ANOVA: P < 0.05). However, the presence of TgFSH had no overall effect on oocyte aneuploidy, as the proportion of aneuploid oocytes was equivalent between genotypes (two-way ANOVA: genotype, P = 0.08) (Figure 2 ).
Cumulus cell gene expression
Relative expression levels of CC transcripts previously proposed as indirect somatic biomarkers of oocyte quality, developmental competence, or ensuing pregnancy were determined by qPCR and examined for changes due to TgFSH expression, oocyte ploidy, and age of females by three-way ANOVA.
Inhba
TgFSH had a significant effect (P < 0.005) upon Inhba expression in CCs. Elevated Inhba expression in CCs from 6-month-old TgFSH vs WT females (2-4 fold, P < 0.05) contrasted with reduced expression in CCs from 12-month-old TgFSH vs WT females (30%-50%, P < 0.05) ( Figure 3A ). In addition, Inhba expression exhibited a ploidy status effect (P < 0.05), likely to reflect 2-3 fold higher expression in CCs with aneuploid vs euploid oocytes from 6-and 12-month-old TgFSH and 12-month-old WT females (P < 0.05).
Rgs2
Rgs2 mRNA levels were significantly affected by ploidy status (P < 0.05) and TgFSH (P < 0.05) ( Figure 3B ). Rgs2 expression was significantly elevated (3 fold, P < 0.05) in CCs associated with aneuploid vs euploid oocytes from 12-month-old TgFSH and WT females.
Serpine2
TgFSH had a significant effect (P < 0.001) upon Serpine2 expression levels in CCs, reflected by higher mRNA levels in 6-month-old TgFSH vs WT females ( Figure 3C ). Serpine2 expression was higher in CCs associated with aneuploid vs euploid oocytes from 6-monthold TgFSH females (2.8 fold, P < 0.05), but not significantly elevated in CCs from aneuploid vs euploid oocytes in other female groups.
Cxcr4
Overall, age, oocyte ploidy, and TgFSH status had no significant effect (two-way ANOVA) on Cxcr4 expression in CCs ( Figure  3D ). However, Cxcr4 expression was significantly higher (2 fold, P < 0.05) in CCs from aneuploid vs euploid oocytes from 12-monthold TgFSH females ( Figure 3D ).
Cyp19
Cumulus cell expression of Cyp19 displayed a ploidy status (P < 0.0005) and TgFSH effect (P < 0.05). Cyp19 expression was significantly higher in TgFSH vs WT euploid oocytes and significantly increased in WT aneuploid vs euploid oocytes ( Figure 3E ). 
Egfr
Age, oocyte ploidy, and TgFSH each had significant effects (P < 0.05, 0.0001, and 0.0001, respectively, two-way ANOVA) on Egfr mRNA levels. A biphasic temporal change in Egfr expression was revealed, with greatly reduced expression (13.6 fold, P < 0.05) in CCs from aneuploid vs euploid oocytes from 6-month-old WT females followed by markedly elevated expression (4.4 fold, P < 0.05) in CCs from aneuploid vs euploid oocytes from 12-month-old WT females. In comparison, Egfr expression levels in CCs from 6-and 12-monthold TgFSH females resembled the pattern found with 12-month-old WT females ( Figure 3F ); higher Egfr mRNA levels associated with aneuploid compared to euploid oocytes (P < 0.05).
Grem1
Age, oocyte ploidy, and TgFSH each had significant effects (P < 0.05, 0.0001, and 0.005, respectively, two-way ANOVA) on CC Grem1 expression. Greatly reduced Grem1 expression (>15 fold, P < 0.05) in CCs from aneuploid vs euploid oocytes from 6-month-old WT females was followed by equivalent expression in CCs from aneuploid vs euploid oocytes from 12-month-old WT females ( Figure 3G ). In contrast, equivalent Grem1 expression in CCs from aneuploid vs euploid oocytes from 6-month-old TgFSH females (resembling the 12-month-old WT pattern) was followed by elevated expression (>5 fold, P < 0.05) in CCs from aneuploid vs euploid oocytes from 12-month-old TgFSH females ( Figure 3G ).
Ptgs2
Overall, age and oocyte ploidy had no significant effect (two-way ANOVA) on Ptgs2 expression in CCs, although Ptgs2 expression was significantly reduced (68%-81%, P < 0.05) in ploidy-matched CCs from 12-month-old TgFSH vs WT females ( Figure 3H ). TgFSH had a significant effect on Ptgs2 expression (P < 0.05), likely to reflect the reduced Ptgs2 mRNA levels in CCs associated with oocytes from 12-month-old TgFSH vs WT females.
Tnfaip6
Age, oocyte ploidy, and TgFSH each had significant effects on CC Tnfaip6 expression (two-way ANOVA, P < 0.05). Elevated Tnfaip6 expression (56%-60%, P < 0.05) in CCs from 6-month-old TgFSH vs WT females contrasted with reduced expression (>2.5 fold, P < 0.05) in CCs from 12-month-old TgFSH vs WT females ( Figure 3I ). Higher Tnfaip6 mRNA levels (P < 0.05) were found in CCs associated with aneuploid vs euploid oocytes from 12-monthold WT females, whereas CC Tnfaip6 expression levels were equivalent with aneuploid vs euploid oocytes from TgFSH females. Expression levels of Has2, Pgk1, and Ctnnd2 transcripts, proposed as CC markers for oocyte developmental [29, 30] , showed no significant changes due to female age, oocyte ploidy, or TgFSH (data not shown).
Embryo transfer and effect of TgFSH on oocyte quality Pregnancy rates
Neither embryo donor age nor exposure to TgFSH (i.e., embryos from TgFSH vs WT donors) had an effect on the percentage of pregnant WT recipients following embryo transfer (Table 2) .
Implantation rates
Analysis of implantation rates for donor WT and TgFSH embryos revealed no overall effect of age or genotype (by two-way ANOVA) ( Table 2 ). However, the proportion of transferred embryos from 12-week-old TgFSH donors that implanted in control WT recipients was significantly reduced (34%, P < 0.05, one-way ANOVA) compared with the percentage of implanted embryos from 12-week-old WT donors (Table 2 ).
Pups at full term
Overall, neither donor age nor exposure to TgFSH had an effect on the proportion of full-term pups that resulted from embryo implantations (two-way ANOVA). However, the proportion of implanted embryos from 26-week-old TgFSH donors that survived to full term in WT recipients was significantly increased (43%, P < 0.005, one-way ANOVA) compared with embryos from 26-week-old WT donors ( Table 2) . Analysis of pup birth weights revealed a significant interaction between genotype and age (one-way ANOVA, P < 0.001). Pups derived from TgFSH donor embryos exhibited equivalent birth weights compared to pups derived from WT donor embryos (Table 2) .
Embryo transfer and effect of TgFSH on surrogate environment Pregnancy rates Recipient age and the presence of TgFSH (i.e., TgFSH vs WT recipients) had no effect on the percentage of pregnant females following embryo transfer (Table 3) . However, pregnancy rates were significantly reduced (65%, Fisher's test, P < 0.05) in 26-week-old TgFSH compared with age-matched WT recipients receiving control WT embryos (Table 3) .
Implantation rates
Analysis of embryo implantation rates in WT-and TgFSH-recipient females revealed no effect of age or genotype of the recipient (Table 3). Control embryos exhibited equivalent implantation rates in TgFSH compared with WT-recipient females.
Pups at full term
Recipient age or the presence of TgFSH had no overall effect on the proportion of full-term pups derived from detected embryo implantations (two-way ANOVA). However, total pups born per litter and the proportion of implanted embryos surviving to full-term pups were both significantly higher (P < 0.05, one-way ANOVA) in 12-week-old TgFSH compared with age-matched WT recipients (Table 3) . However, the birth weight of pups was significantly Downloaded from https://academic.oup.com/biolreprod/article-abstract/98/4/491/4819280 by OUP site access user on 08 October 2018 reduced (14%-16%, P < 0.001) in 12-and 26-week-old TgFSH recipients compared with age-matched WT recipients (Table 3) .
Discussion
We previously found that female mice expressing progressively rising serum levels of TgFSH with age became subfertile without exhibiting reduced ovulation or fertilization rates [20] . Increased early embryo resorption suggested a decline in oocyte quality in TgFSH mice [20] ; however, our present study revealed that elevated FSH had no effect on oocyte quality in subfertile TgFSH females. Candidate CC biomarkers (e.g., Inhba and Rgs2 mRNA levels) for early embryo quality were altered by high FSH and oocyte aneuploidy, which may require consideration in the use of such markers as a diagnostic tool for oocyte quality. However, high FSH had no impact on the level of oocyte aneuploidy in TgFSH females. In addition, embryo transfer studies revealed that high FSH levels had no major negative effect upon embryo developmental competence in vivo, indicating that declining fertility in TgFSH females was not caused by loss of embryo quality per se.
Oocytes from subfertile (6-month-old) TgFSH females displayed normal developmental competence during IVM. However, elevated FSH activity hindered the developmental competence of oocytes isolated from TgFSH females aged 12 months and onwards. Fewer oocytes from these older TgFSH females reached the MI or MII stages because of stalled development at the GV stage. It is possible that exposure to higher levels of FSH present in older TgFSH females caused the partial disruption of oocyte development [20] , but the underlying mechanism remains unknown. Likewise, TgFSH only appeared to affect oocyte aneuploidy in old females (24 months), well after the loss of fertility. Normal levels of oocyte aneuploidy were found in TgFSH females aged 6-18 months. Therefore, continual in vivo exposure to rising TgFSH did not replicate the increased level of murine oocyte aneuploidy observed after the exposure of COCs to high FSH during IVM [19] . Overall, in vitro criteria suggested that oocyte quality remained normal in subfertile TgFSH females despite exposure to persistent high levels of FSH and elevated ovulation.
Specific gene expression levels in CCs may provide useful biomarkers for oocyte developmental competence in vitro. Previous studies found that increased levels of Has2 [31] [32] [33] , Grem1 [31] [32] [33] [34] [35] , Ptgs2 [32, 35] , Tnfaip6 [36, 37] , and Inhba [38] were associated with improved oocyte developmental competence. Increased transcript levels of Cyp19 [33] , Serpine2 [33] , Pgk1 [29] , and Rgs2 [29] were linked with more successful pregnancy outcomes. Expression of Cxcr4 [30] and Ctnnd2 [30] were inversely correlated with better embryo development and embryo quality. In the current study, several genes exhibited altered expression in CCs from TgFSH oocytes, including Serpine2, Cxcr4, and Cyp19. Elevated expression of Serpine2 in CCs from TgFSH oocytes was consistent with its responsiveness to FSH in cultured bovine granulosa cells [39] . However, high Serpine2 impaired murine oocyte IVM [40] , which may be consistent with partly impaired IVM of GV oocytes from older TgFSH females. Elevated Serpine2 mRNA levels in CCs from aneuploid compared with euploid oocytes from subfertile (6-month-old) TgFSH females may also preclude its use as a biomarker for oocyte quality. In comparison, CC Cxcr4 expression was higher with aneuploid compared with euploid oocytes from older (12-month-old) TgFSH females. Cxcr4 encodes a chemokine receptor [41] , and upregulated expression of Cxcr4 in CCs was found with hypoxic conditions [30, 42] or delayed oocyte maturation [30] . Disrupted maturation of GV oocytes from older TgFSH females appears consistent with elevated Cxcr4 expression; however, Cxcr4 was not a marker for aneuploidy in normal females. TgFSH significantly elevated Cyp19 expression in CCs associated with euploid oocytes. Past work found that Cyp19 mRNA expression was higher in human follicles of oocytes that led to pregnancy during IVF [33] . However, our current data revealed that Cyp19 mRNA levels were elevated in CCs from aneuploid vs euploid oocytes from normal (non-Tg) females, which raises a caution using Cyp19 as a biomarker for oocyte quality.
Several genes exhibited elevated expression in CCs associated with aneuploid oocytes in particular groups of females. For example, Inhba expression was higher in CCs associated with aneuploid compared with euploid oocytes from TgFSH and older normal females. Inhba was previously examined as a potential biomarker of oocyte competence [33, 43] . Serum inhibin A levels form part of multiple-marker screening for aneuploidy [44] , and were elevated in aged TgFSH female mice [22] . Expression of Inhba mRNA was not elevated in CCs with aneuploid oocytes from younger (6-month-old) normal females, suggesting a temporal complication using CC Inhba transcripts as a potential biomarker for oocyte aneuploidy. Our current finding of elevated expression of Rgs2 in CCs with oocytes displaying aneuploidy in older normal mice may confound its proposed use as a predictive biomarker for embryo developmental competence [45] or pregnancy potential [29] in human IVF; noting more recent work indicated Rgs2 expression was not a suitable biomarker for implantation success [46] .
We observed that Egfr and Grem1 each displayed biphasic temporal expression patterns in CCs associated with aneuploid relative to euploid oocytes. Markedly reduced expression in CCs from aneuploid oocytes from younger (6 month) females was followed by elevated or normal expression with aneuploid oocytes from older females. FSH upregulated Egfr expression in mouse granulosa/CCs [47] , and augmented EGFR actions in porcine CCs [48] , consistent with upregulated Egfr expression in CCs from most TgFSH female groups examined. The reduced Egfr and Grem1 mRNA levels in CCs associated with aneuploid oocytes in the younger females remains unexplained. EGFR-dependent upregulation of downstream transcripts, such as Has2 (hyaluronan synthase 2), Ptgs2 (prostaglandinendoperoxide synthase 2), and Tnfaip6 (tumor necrosis factor, alpha-induced protein), is required for cumulus expansion [47] . Cumulus cell expression patterns of Has2, Ptgs2, and Tnfaip6 in the different female groups did not follow Egfr expression patterns. Has2, Ptgs2, and Tnfaip6 transcript levels were proposed as potential biomarkers for bovine or human oocyte selection in IVF [31, 33, 35] . However, CC Has2 expression was variable and not altered by TgFSH or ploidy status in the current study. In contrast, elevated Ptgs2 expression was found in CCs from aneuploid ooctyes from TgFSH but not normal females, whereas higher Tnfaip6 mRNA levels were found in CCs associated with aneuploid oocytes from normal but not TgFSH females. Cumulus cell Grem1 was also proposed as a biomarker for bovine [33] or human [31, 35, 49] oocyte developmental potential during IVF. TgFSH appeared to upregulate Grem1 expression in CCs associated with aneuploid oocytes, but had no effect on Grem1 mRNA levels associated with euploid oocytes.
All CC transcripts examined in our current paper have been proposed as biomarkers for oocyte quality, maturation-development potential and/or pregnancy outcome. Several transcripts (e.g., Inhba, Egfr, and Rgs2) displayed higher expression in CCs associated with aneuploid oocytes, which suggests careful consideration is required when using these CC transcripts as indirect biomarkers under certain circumstances, such as conditions with elevated FSH activity.
To selectively examine the developmental potential of oocytes exposed to high FSH in vivo, embryos were transferred from TgFSH females to normal recipients. Embryos from fertile (3-month-old) TgFSH vs WT females had reduced uterine implantation (in a normal maternal environment), which led to less total full-term pups. However, the TgFSH embryos that implanted had a normal survival rate. Therefore, embryos from fertile TgFSH females displayed reduced preimplantation but normal postimplantation survival. High doses of gonadotrophins reduced embryo preimplantation in mice [15] [16] [17] , as well as reduced implantation and postimplantation; however, these studies did not distinguish between high FSH or LH actions, and did not examine effects of persistent FSH elevation.
In contrast to embryos from fertile TgFSH females, embryos from subfertile (6-month-old) TgFSH females displayed higher than normal uterine implantation rates and higher survival rates postimplantation. Therefore, persistent elevation of FSH activity had no negative impact upon the developmental potential of oocytes isolated from subfertile TgFSH females. A mechanism for the elevated survival of embryos preexposed to high FSH remains undetermined. Previous studies have shown that single high-dose gonadotrophin superovulation regimen led to reduced oocyte-embryo quality [13, 14] . However, repeated superovulation in mice overcame this effect on embryo quality, suggesting compensatory in vivo mechanisms adjust for sustained high gonadotrophin exposure [18] . In the current study, the impact of elevated FSH upon the maternal/uterine environment was deliberately circumvented (via normal recipients) to selectively examine oocyte potential from TgFSH females. The increased developmental competence of transferred embryos from 6-month-old TgFSH females shows that persistent FSH activity may provide one compensatory mechanism, conferring an unexpected positive effect inherent to developing oocyte-embryos via pathways yet to be determined.
The selective effect of elevated FSH upon the maternal/uterine environment was determined by comparing normal (non-Tg) embryo outcomes after transfer to TgFSH or normal recipients. Normal embryos displayed normal rates of uterine implantation in TgFSH female recipients. Postimplantation survival was elevated or normal in 3-or 6-month-old TgFSH females, respectively. In other words, the transfer of normal oocytes restored the fertility of subfertile TgFSH females. Overall, elevated FSH levels in TgFSH females had no major adverse effects, in terms of embryo-fetal survival, on either oocyte potential or maternal environment in respective transfer experiments. Neither TgFSH oocyte donors nor recipients were able to replicate the reduced postimplantation survival previously observed in aging naturally bred TgFSH dams [20] . Excessive embryo resorption previously found in TgFSH dams [20] may reflect an age-related reduction in the loading capacity of the uterus [50, 51] , although equivalent embryo numbers were transferred to agematched TgFSH and normal recipients in the current study. Our findings do not rule out impaired postimplantation embryo survival reflecting more complex and combined subtle effects of elevated TgFSH actions upon both the ovary and maternal/uterine function. Nevertheless, any "dual" ovary-uterine effects upon postimplantation survival were corrected by either transferring embryos from TgFSH donors into a normal uterine environment, or donating normal embryos to TgFSH-recipient females.
Birth weights of pups from TgFSH-recipient dams were slightly reduced compared to normal recipients, demonstrating elevated FSH altered the optimal maternal/uterine environment. Smaller pups from TgFSH dams was consistent with findings that women of advanced maternal age (>35 years old) have elevated FSH levels and an increased risk of producing low birth weights [52] [53] [54] . Our data also support research showing that exogenous gonadotropin stimulation (recombinant human FSH or equine chorionic gonadotropin) altered the murine preimplantation maternal environment, reduced pregnancy rates, and perturbed fetal development [16] . In contrast, oocytes from TgFSH donors (fertile or subfertile) produced pups with normal birth weights when transferred to normal recipients, showing reduced birth weight is unrelated to "oocyte" exposure to high FSH.
In summary, our TgFSH model demonstrated that exposure to elevated FSH in vivo affected oocyte developmental competence in vitro, but only for oocytes from old TgFSH females. Similarly, persistent FSH elevation had no effect upon oocyte aneuploidy in TgFSH females until well beyond the age of reproductive failure. While not accounting for the reduced fertility of TgFSH females, reduced oocyte IVM and increased aneuploidy may reflect dosedependent FSH actions caused by higher levels of FSH in older females. Expression levels of specific transcripts (proposed biomarkers for oocyte selection) in CCs were altered by oocyte aneuploidy and/or TgFSH, indicating further investigation is needed in using such biomarkers for assisted reproduction. Embryo transfer revealed that TgFSH embryos developed normally in a normal host environment, showing rising FSH had no adverse effect on oocyte-embryo developmental potential. Normal embryos had normal implantation and survival rates in TgFSH recipients, but yielded reduced birth weights, indicating that high FSH reduced the optimal maternal/uterine environment. We propose that the high embryo-fetal mortality in aging TgFSH dams reflects complex combined ovarianuterine effects of elevated FSH. Recently, an alternative concept of ovarian aging proposed that aging ovarian environments, rather than aging oocytes, drive the declining fertility in older women [55] . Our TgFSH mice may represent an endocrine-initiated paradigm of this concept, featuring an altered ovarian environment rather than oocyte quality associated with premature female reproductive aging.
